Bought a few of these as the news seems to be getting better and I am sure we have now seen the bottom

ains




Maelor Approved to Hold CE Marks


Maelor plc, the AIM quoted specialist healthcare products company, is pleased to
announce that its wholly-owned subsidiary, Maelor Pharmaceuticals Limited, has
been certified to hold its own CE Marks for medical devices associated with
sterile catheter irrigation solutions.


Maelor CEO Stephen Appelbee said:


'This approval is important because it will enable us to develop and launch our
own product brands using a Maelor CE Mark. This now allows us to accelerate the
launch programme of our range of sterile catheter irrigation solutions into
several worldwide markets under our own brand. Now that we have established our
certified status it will be a straightforward process to extend this to other
devices being developed from our pipeline.


It is also formal recognition that Maelor maintains the highest quality
standards in the development and manufacture of its products

cynic I know! But I still get fan mail---strange is it not.

Who in their right mind would want to be in contact with you...LOL.

you would be very surprised

Surprise me ...LOL.

I REGRET THAT YOU ARE NOT IN THE APPROPRIATE CATERGORY TO RECEIVE SUCH INFORMATION!

More proof of your Walter Mitty existence...LOL.

beemer ... stop allowing yourself to be dragged into the tedious bore's inane droning.

or rather proof of the exitance of the peasantry---- would you not say.

Cynic I thought that you may have had a little more stamina.

Tenby

While you are being a tedious bore the SP of COH is still going north...the more you say it will go down it goes up...thanks.

"If we don't believe in freedom of expression for
people we despise, we don't believe in it at all."
-Noam Chomsky

Get read for the big bust out------
7. Maelor

Maelor is a specialist pharmaceutical and medical devices company in the critical care arena. A number of its products are 'must have' and represent 'life or death' for the patient. Its flagship critical care product, Volplex, is a blood plasma substitute that is used in operating theatres and hospital wards when a patient sustains heavy bleeding and requires fluid replacement. Since the sale of Volplex was brought back in-house following a strategic review by new management last June, Maelor's share of this market has doubled from 10 to 20 per cent. Competition is limited with only one other competitor, so there is still substantial room for growing market share.

However, the main reason for investing in Maelor is the transformational takeover of Acorus, which completed in May and funded by a 8m placing at 10p. Overnight, this has trebled the companys market capitalisation, strengthened and consolidated its niche position in the UK specialist critical care hospital market, and catapulted it into profitability. Acorus is a profitable and rapidly growing hospital specialist company with a highly synergistic portfolio of products also primarily focused in critical care.



Maelor says the acquisition of Acorus as transformational will create a strong, profitable business with positive cash flow. What the market seems to have failed to notice is that, as a division within Maelor, Acorus could have made an operating profit of 1.5m in 2006 against the 840,000 reported. In addition, with the acquisition of Acorus, which has much higher gross margins, margins for the enlarged group are forecast to rise further to 59 per cent from the 48 per cent reported in final results to March. The group is debt free and has an unused debt facility of 2m, which provides further funds for further bolt-on acquisitions. Trading since the period end is in line with expectations and, at 13.8p, its shares are on a modest multiple of 9.9 for the year to March 2009, when the benefits of the acquisition should really flow through. In May, there was cluster buying of 165,000-worth of shares by five directors at the placing price. The potential launch of Isoplex - a complementary product to Volplex - in 2008 is not factored into broker forecasts, either, which leaves the shares looking like a strong buy.




Source: Company REFs as at 21.06.07. *Source: Numis Securities. ** Classified under pharmaceuticals and biotechnology.

Nigel Milton owns shares in Celsis International, Corin, Deltex Medical, Maelor and Synergy Healthcare. During 2006, Nigel Miltons stock picks highlighted in the Best Small Stocks for 2006 feature in the Investors Chronicle (30 December 2005 issue) on average rose by 48.8 per cent.

In the true Adieh and BMW mannerism I post thusforth: MLR doing well this morning.

I SINCERELY TRUST THAT SOME OF YOU MAY HAVE BOUGHT MLR ON MY SUGGESTION.

I have a short term target price of 50p.

This share was trading at 2 pounds about 6 years back and on a lot less in fundamentals than it has today.

Good luck all.

Rise won't last...beware.

Well said Mr NEVERBEENER---NOW KINDLY PROVE YOU CONTENTION PLEASE WITH FACTS AND FIGURES.

The sp will inevitably fall back over the next few days...

My advice is to get into COH...great potential.

Its the weekend over the next few days stupid and the market is closed

Since you uneducatedly gobbed last the bid has moved up!

Nothing to sustain the rise...it will inevitably fall back.

Another tip...BKE UP 40%+ TODAY.

Rubbish MLR is undervalued--any idiot can see that.

BKE-- sorry I dont bother with no hopers.